Close Menu

This story has been updated to include information about Twist Bioscience's filing for a stock offering worth up to $200 million. 

NEW YORK – Twist Bioscience is looking to deliver new products based off its synthetic DNA manufacturing platform as well as new biopharma partnerships over the rest of fiscal year 2020.

The San Francisco-based firm will be expanding its product line in several directions, CEO and Cofounder Emily Leproust said on a conference call on Wednesday following the release of the firm's fiscal fourth quarter and full-year 2019 financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.